Advertisement
Advertisement

TheBodyPRO.com covers EACS 2013

Building a Better HIV Drug: Nano-Formulated Medicines

December 18, 2013

 5/7 

Limitations of Long-Acting Formulations

Limitations of Long-Acting Formulations

While having long-acting drugs will reduce the frequency of doses, there are some limitations, Owen noted.

For one thing, treatment interruptions won't be possible, which is particularly a concern when the need arises to manage an acute event (such as surgery or coinfection), pregnancy or the patient's desire to take a drug holiday.

There also are no strategies yet for how to manage drug-drug interactions between long-acting antiretrovirals. Furthermore, we don't yet know how appropriate long-acting drugs would be for patients with high viral loads. But hopefully with more research and trials, these concerns can be addressed.






This article was provided by TheBodyPRO.com. It is a part of the publication The 14th European AIDS Conference (EACS 2013).
 


No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement